Cannabinoid CB 1 receptors are densely expressed on striatal projection neurons expressing dopamine D 1 or D 2 receptors. However, the specific neuronal distribution of CB 1 receptors within the striatum is not known. Previous research has established that the endocannabinoid system controls facilitation of behavior by dopamine D 2 receptors, but it is not clear if endocannabinoids also modulate D 1 receptor-mediated motor behavior. In the present study, we show that cannabinoid CB 1 receptor mRNA is present in striatonigral neurons expressing substance P and dopamine D 1 receptors, as well as in striatopallidal neurons expressing enkephalin and dopamine D 2 receptors. We explored the functional relevance of the interaction between dopamine D 1 and D 2 receptors and cannabinoid CB 1 receptors with behavioral pharmacology experiments. Potentiation of endogenous cannabinoid signaling by the uptake blocker AM404 blocked dopamine D 1 receptor-mediated grooming and D 2 receptor-mediated oral stereotypies. In addition, contralateral turning induced by unilateral intrastriatal infusion of D 1 receptor agonists is counteracted by AM404 and potentiated by the cannabinoid antagonist SR141716A. These results indicate that the endocannabinoid system negatively modulates D 1 receptor-mediated behaviors in addition to its previously described effect on dopamine D 2 receptor-mediated behaviors. The effect of AM404 on grooming behavior was absent in dopamine D 1 receptor knockout mice, demonstrating its dependence on D 1 receptors. This study indicates that the endocannabinoid system is a relevant negative modulator of both dopamine D 1 and D 2 receptor-mediated behaviors, a finding that may contribute to our understanding of basal ganglia motor disorders.
INTRODUCTION
Cannabinoid CB 1 receptors are expressed in brain areas that contribute to movement such as the basal ganglia. The highest concentration of CB 1 receptors is found in the striatum, where they colocalize with dopamine D 1 and D 2 receptors in striatal neurons (Herkenham et al, 1990 (Herkenham et al, , 1991 Tsou et al, 1998; Hermann et al, 2002; Julián et al, 2003) . However, their regional and neuronal distribution has not been established. It is known that there is a continuous release of endogenous cannabinoid CB 1 receptor agonists such as anandamide in the brain, and that these endogenous agonists exhibit neurotransmitter function (Giuffrida et al, 1999; Baker et al, 2000) . The endocannabinoid system can act as a modulator of dopaminergic neurotransmission in the basal ganglia (Cadogan et al, 1997; Glass and Felder, 1997; Pertwee, 1999; Giuffrida et al, 1999; Beltramo et al, 2000; Gerdeman and Lovinger, 2001; Gubellini et al, 2002) . Endogenous cannabinoids have been proposed to act in a homeostatic mechanism in the basal ganglia by activating CB 1 receptors, which appear to function as a brake on dopaminergic function in the striatum (Rodriguez de Fonseca et al, 1994 .
Although much is known about the central effects of exogenously applied cannabinoids, the functional relevance of the endogenous cannabinoid system needs further investigation. In this context, the discovery of the highly potent CB 1 receptor antagonist, SR141716A, and the indirect agonist N-(4-hydroxyphenyl)-arachidonamide (AM404, which acts as an anandamide uptake blocker) have opened new possibilities for the identification and characterization of cannabinoid-dependent function. Particularly, the use of SR141716A has shown a close relationship between CB 1 receptors and striatal dopamine D 1 , and D 2 receptor-mediated functions (Rodriguez de Fonseca et al, 1994 . AM404, through blockade of the endocannabinoid transporters, causes accumulation of anandamide and 2-arachidonoylglycerol (2-AG), prolonging dopamine-mediated responses of endogenous cannabinoids (Beltramo et al, 2000; Glaser et al, 2003) . The effects of CB 1 receptor antagonists in the striatum are proposed to be due to release from the inhibitory influence of endogenous CB 1 receptor agonists on striatal dopamine D 2 receptor function (Rodriguez de Fonseca et al, 1994 Giuffrida et al, 1999) . However, several studies suggest that D 1 and CB 1 receptors also interact negatively in several rodent behaviors (Sañudo-Peña et al, 1998a) . Determining the functional interaction between CB 1 and D 1 and D 2 receptors in the striatum is important for understanding neurochemical changes in diseases such as Parkinsonism and schizophrenia and in adaptive processes including the rewarding effects of drugs of abuse. Dopamine receptor agonists and antagonists are currently used therapeutically for these disorders and there is emerging evidence that CB 1 cannabinoid receptor antagonists have a therapeutic effect in some of these disorders as well (Fernandez-Espejo et al, 2005; Sañudo-Peña et al, 1998b) .
The functional interaction between striatal CB 1 and D 1, and D 2 dopamine receptors can be studied by examining the effect of pharmacological modulation of these receptors on motor activity in rats. Because dopamine agonists injected into the striatum induce turning behavior, this behavioral response represents an index of dopaminergic imbalance between the two hemispheres (Ungerstedt and Arbuthnott, 1970; Schwarting and Huston, 1996; Gerfen et al, 1990; Keefe and Gerfen, 1995; Pavón et al, 2006) . For example, unilateral intrastriatal injection of D 1 receptor agonist induces contralateral turns (Keefe and Gerfen, 1995; Pavón et al, 2006) . D 1 and D 2 receptor functions can be assessed through specific behavioral patterns as well, since these behaviors are mostly modulated at the striatal level (McPherson and Marshall, 1996; Davidkova et al, 1998) . Some of these responses are mediated by D 2 receptors, like oral movements (mouth fasciculation, yawning, biting, licking) while others like grooming are mediated by dopamine D 1 receptor stimulation (Molloy and Waddington, 1984; Starr and Starr, 1986a, b; McPherson and Marshall, 1996) . These behaviors have been extensively studied using in vivo pharmacology and electrophysiology and have been shown to reflect striatal function (Aldridge and Berridge, 1998) .
We hypothesized that endogenous cannabinoids modulate both D 1 and D 2 dopamine-induced motor behaviors through the interaction of CB 1 receptors. To characterize the functional neuroanatomy of cannabinoid receptor interaction in the basal ganglia, we analyzed the distribution of cannabinoid CB 1 receptors and dopamine D 1 and D 2 receptors in the striatum. To assess the functional role of endogenous cannabinoids in behavioral responses mediated by dopamine D 1 or D 2 receptors, we examined turning behavior, grooming, and oral stereotypies. We also used a dopamine D 1 receptor knockout (D 1 R À/À ) mouse to support further the specificity of the responses studied.
MATERIALS AND METHODS

Animals
Studies were carried out in inbred adult male Wistar rats, ranging from 2 to 3 months old, weighing 250-300 g or in male wild-type and dopamine D 1 receptor knockout (D 1 R À/À ) mice (Xu et al, 1994; Moratalla et al, 1996) derived from the mating of heterozygous mice, weighing 24-28 g. The genotype of each mouse was determined by genomic Southern blot analysis. Animals were housed in a temperature-controlled room (22 ± 11C) on a 12-h light-dark cycle (lights on at 0800 h) with free access to food and water. The maintenance of animals and the experimental procedures were approved by the bioethical committee at the Cajal Institute and followed the guidelines from the European Union (Council Directive 86/609/EEC).
Drugs and Doses
The dopamine D 1 receptor agonists SKF38393 or SKF81297 (Tocris, Bristol, UK) dissolved in double distilled water and quinpirole (a dopamine D 2 receptor agonist, RBI, Natick, USA) dissolved in 20% ethanol were administered at 0, 0.5, and 1 mg/ml for intrastriatal injections and 5 mg/kg (SKF38393, SKF81297) or 1 mg/kg (quinpirole) for subcutaneous administration. The D 2 receptor agonist bromocriptine and CB 1 agonist HU-210 (Tocris, UK) were each dissolved in 10% ethanol with double-distilled water. Bromocriptine was administered by intrastriatal injection at 0.5 and 10 mg/ml, and HU-210 was administered at a dose of 20 mg/kg, i.p. (intraperitoneal). The CB 1 antagonist SR141716A (gift from Sanofi-Synthelabo Recherche, France), dissolved in 20% DMSO, was administered at 0, 1, and 1.5 mg/ml for intrastriatal injection or 0.3 and 1 mg/kg, i.p. AM404 (the anandamide uptake blocker, Tocris), dissolved in Tween 80 : propylen glycol : saline (5 : 5 : 90, by vol/vol), was administered at 0, 2.5, and 5 mg/ml for intrastriatal injection and 0.3 or 10 mg/kg for i.p. administration. Local injections in the striatum were performed in a volume of 1.5 ml. In each case, the same volume of appropriate vehicle was used for the 0 dose. We followed a previous method for selecting the injection site (Routtenberg, 1972) . Using this method, an injection of 1.5 ml diffuses over approximately 3 mm 3 , sufficient to affect a significant area of the striatum (Routtenberg, 1972) . When postmortem analysis revealed injection sites that were off the target area, those animals were not included in the analysis.
Tissue Preparation for In Situ Hybridization
Rats were euthanized by rapid decapitation and their brains were quickly removed, frozen in dry ice and stored at À801C. Complete rostro-caudal series of coronal sections (12 mm thick) were cut in a cryostat (Leica, Wetzlar, Germany), thaw mounted onto microscope slides, air-dried and stored at À801C.
Riboprobe Synthesis and Labeling
We used the following riboprobes: a 492 bp cRNA probe complementary to rat preproenkephalin (pro-Enk) cDNA plasmid provided by Dr Sabol (NIH, Maryland, USA); a 480 bp cRNA for rat b-preprotachykinin, substance P (SP), provided by Dr James E Krause (Branford, USA); a 430 bp cRNA for rat somatostatin (Som), provided by Dr Cacicedo (Hospital Ramón y Cajal, Spain); a 700 bp cRNA for rat parvalbumin (PVB), provided by Dr Berchtold, (Universitat Zurich, Switzerland); a 694 bp cRNA for rat choline acetyltransferase (ChAT), provided by Dr Berrard (Hôpital de la Pitié Salpêtriere, Paris); a 326 bp cRNA for rat glutamic acid decarboxylase 67 (GAD67), provided by Dr Tillakaratne (University of California, USA), and a 1619 bp cRNA for the human CB 1 receptor provided by Dr Santos (Universidad Complutense de Madrid, Spain). Riboprobes were labeled with 35 S-isotope ( 35 S-CTP) or with digoxigenin 11-UTP to carry out dual in situ hybridization. Riboprobes were synthesized by in vitro transcription as in Julián et al (2003) . Briefly, 1 mg of the appropriate template was reacted with 350 mCi of a 35 S-CTP (1000 Ci/mmol, NEN, MA, USA), 50 mM unlabeled CTP, 20 mM each of ATP, GTP, and UTP, 15-20 units of the appropriate RNA polymerase, 100 mM of dithiothreitol (DTT), and 20 units of RNasin (Promega Corporation, Madison, USA) for 1 h at 371C. Digoxigeninlabeled probes were synthesized with 1 mg of the appropriate template, 2 ml of digoxigenin RNA labeling mix (10 Â ) (Roche Molecular Biochemicals, Mannheim, Germany), 15-20 units of appropriate RNA polymerase and 20 units of RNasin and incubated for 2 h at 371C. Labeled riboprobes were purified by ethanol precipitation and resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.6) containing 100 mM DTT (for 35 S labeled probes only) and 40 units of RNase inhibitor and stored at À801C.
In Situ Hybridization
Selected sections were fixed in 4% paraformaldehyde, acetylated, rinsed in PBS, dehydrated with ethanol, and defatted in chloroform.
35
S-labeled CB 1 receptor riboprobe (alone or in combination with a digoxigenin-labeled riboprobe chosen as a marker of striatal neurons) were mixed in a hybridization solution, applied to sections, and hybridized for 12 h at 601C. Radioactive labeled probes were diluted in the hybridization solution to reach a 60 000-80 000 c.p.m./ml and digoxigenin-labeled probes were diluted 1 : 100. After hybridization, slides were rinsed in saline sodium citrate solution (SSC), treated with RNase A (100 mg/ml) and finally washed in SSC at 651C. For single in situ hybridization, slides were placed in cassettes and exposed to Hyperfilm bMax (Amersham Pharmacia Biotech, Barcelona, Spain) for 3-5 days. Films were developed in D-19 (Eastman Kodak, NY, USA) and analyzed with an image analysis system. For dual in situ hybridization, slides were processed to detect the second mRNA labeled with digoxigenin. Slides were incubated overnight with alkaline phosphatase-conjugated polyclonal anti-digoxigenin antiserum (Roche Molecular Biochemicals) diluted 1 : 1000. The following day, slides were incubated in the dark with nitro blue tetrazolium, (NBT, 0.34 mg/ml) and 5-bromo-4-chloro-3-indolyl-phosphato (BCIP; 0.175 mg/ml). Reaction progress was monitored with a light microscope for the development of color. After exposure to Hyperfilm bMax films, selected slides were dipped in nuclear track emulsion LM1 (Eastman Kodak, New York, USA) diluted 3 : 1 in distilled water with 0.1% glycerol, stored in the dark with desiccant and developed after 2-6 weeks.
In Situ Hybridization Analysis
Quantitative analysis of CB 1 receptor mRNA on each striatal neuronal population was carried out by quantifying the number of silver grains and their distribution in digoxigenin-labeled neurons using a computer assisted image system (Qwin 500, Leica Microsistemas SA, Barcelona, Spain). Both the area of the neuronal profile (mm 2 ) and the number of grains present within the area were recorded and used to compute the intensity of labeling of each neuron (expressed as grains per 1.000 mm 2 ). For each striatal neuronal population, we quantified grains over a minimum of 2000 neurons per hemisphere. We used three animals, two coronal sections (200-300 mm apart) per animal. Statistical analysis was performed by one-way analyses of variance (ANOVA) with a repeated measures design, followed by Student's t-test and post hoc comparison with Bonferroni-Dunnet test for each population of striatal neurons to determine differences in CB 1 receptor expression. Differences with a so0.05 were considered significant.
Behavioral Studies
Grooming and oral movements. Rats and mice (eight per group) were handled and placed in a glass observation box of 30 Â 40 Â 30 cm for a week. For behavioral studies, animals were videotaped in the familiar glass box and the time spent grooming and the number of oral stereotypies were registered by trained observers blind to the experimental conditions, as described previously (Beltramo et al, 2000; Giuffrida et al, 1999) . Grooming behavior and oral movements were scored over 5 min intervals at 5, 15, 30, and 60 min after the injection. Data are presented as a sum of all time intervals (mean±SEM). Statistical analysis was performed using one-or two-way analysis of variance (ANOVA) followed by Student or Newman-Keuls post hoc test. These analyses were completed using STATA program (Intercooled Stata 6.0, Stata Corporation, College Station, TX). A probability level of 5% (po0.05) was considered significant.
Rotational behavior. Local injections in the rat striatum were carried out with a guide cannula implanted a week before the experimental studies. The guide cannula (22 gauge stainless steel) was placed in the rat striatum, under anesthesia, with a Kopf stereotaxic frame, 2 mm above the corresponding infusion site (coordinates in mm from bregma and dura, AP ¼ + 0.5, L ¼ À3, and V ¼ À5.5; Paxinos and Watson, 2005) , fastened to the skull with dental cement and fitted with a 30-gauge stainless steel obturator. Injections were performed in the home cage, replacing the obturator cannula by a 30-gauge internal cannula (Small Parts, Miami, USA) connected to a Hamilton syringe and a delivery pump. Solutions were injected over a 5 min period, and afterwards the internal cannula was removed and the obturator cannula replaced. There were 8-10 animals in each group for behavioral studies. To study effects of compounds alone, SKF38393, quinpirole, bromocriptine, or CB 1 ligands were infused at different doses in different groups. To study the interaction between dopaminergic and cannabinoid systems we used vehicle, 0.5 or 1 mg/ml SFK38393, following a Latin square type design, changing the initial dose of dopaminergic ligand for every rat (one group of rats for each dopaminergic ligand). Vehicle, SR141716A (1.5 mg/ml) or AM404 (5 mg/ml) were injected 5 min before SKF38393. These doses elicit maximum turning behavior. If both cannabinoid ligands were injected, SR141716A was injected 5 min before AM404, and SKF38393 was injected 5 min after AM404. Locomotor directional bias was evaluated by quantifying ipsilateral and contralateral rotations induced by the infusion of compounds alone or in combination. Rotations were quantified for 60 min following injections with a rotometer system (Panlab, Barcelona, Spain). For statistical analysis we used one-way ANOVA for drugs administered alone (drug dose as factor) and two-way ANOVA for combinations of drugs (SKF38393 dose as within variable, treatment as in between factor), followed by post hoc comparisons with Tukey's test for drug interactions. After completion of experiments, rats were anesthetized and perfused transcardially with 4% paraformaldehyde. Brains were removed and stored in PBS at 41C, for subsequent sectioning (50 mm). Brain sections were mounted on slides and stained with cresyl violet to examine cannula placements.
RESULTS
Expression of CB 1 Receptor mRNA in Substance P-and Enkephalin-Expressing Striatal Neurons
The hybridization signal obtained with each of the riboprobes used in this study was specific and reproducible. The specificity of the probes was determined by hybridizing with labeled sense riboprobe, which did not yield any signal, and by including a 25-fold excess of cold cRNA in the hybridization solution, which obliterated the signal. Sections hybridized with the CB 1 receptor antisense riboprobe demonstrated an intense signal in the striatum consistent with our previous single-label study of CB 1 receptors in the rat (Julián et al, 2003) and other studies (Hermann et al, 2002) . CB 1 mRNA expression exhibited a lateromedial gradient, more intense in the lateral striatum with a gradual decrease to a less intense signal in the medial striatum ( Figure 1) . Interestingly, towards the medial striatum, signal intensity was higher in patches reminiscent of striosomes, with lower signal intensity in the surrounding matrix (Julián et al, 2003) . Similar results were obtained with emulsiondipped slides; neurons in the lateral part of the striatum had more intense signal than those in the medial part. Signal in the nucleus accumbens was low ( Figure 1 ). To determine whether CB 1 receptors in the striatum are coexpressed with dopamine D 1 or D 2 receptors, we conducted dual-label hybridization experiments with 35 S-labeled riboprobe for CB 1 receptor in combination with digoxigenin labeled riboprobes for preproenkephalin (Enk, a marker for neurons that express D 2 receptors) or b-preprotachykinin (SP, marker for neurons that express D 1 receptors). For quantitative analysis, a set of slides with sections from three different brains was prepared and hybridized simultaneously using a single batch of 35 S-cRNA probe for CB 1 receptor together with either Enk or SP digoxigenin-labeled probes. These slides were processed, dipped in emulsion and developed in parallel. We then counted labeled and double-labeled neurons in the dorsal striatum, which we define to include the entire caudo-putamen, excluding the nucleus accumbens. The probe for CB 1 receptor produced clusters of silver grains over almost all neurons in the striatum (Figures 1-3 and 5) that were substantially greater than the autoradiographic background density, indicating that the majority of striatal neurons express CB 1 receptors. Both types of striatal projection neurons, Enk-and SPexpressing, were labeled with approximately similar signal intensity (Figure 2a ) and the CB 1 receptor silver grain distribution had a Gaussian shape in both populations (Figure 2b ).
Digoxigenin-labeled probes are less sensitive than 35 Slabeled probes, thus we confirmed that CB 1 receptors are expressed in both types of striatal projection neurons by repeating the dual hybridization experiments using digoxigenin label for CB 1 receptors and radioactivity for Enk and SP. The results of these experiments were consistent with the results described above (Figure 3) . Therefore, we conclude that CB 1 receptors are coexpressed with dopamine D 1 receptors in SP neurons and with D 2 receptors in Enk neurons.
To determine whether CB 1 receptor expression is more prominent in direct or indirect striatal pathway neurons, we S-CB 1 -positive neurons expressing substance P. These studies were carried out in three different animals, with two coronal sections from each animal. Between 2000 and 2500 CB 1 -receptor-positive neurons were counted in each striatum. Pairwise comparisons revealed that about 40% of all CB 1 receptor expressing neurons in the striatum were Enkpositive and about 60% were SP-positive. Similar percentages were found in all the striatal territories studied: dorsolateral, ventrolateral, and dorsomedial, in spite of the dorsomedial gradient in CB 1 receptor expression (Figure 4) . Since there are equal number of Enk-and SP-positive neurons in the striatum (Bolam et al, 2000) , these results indicate that CB 1 receptors are more widely coexpressed with dopamine D 1 receptors than with D 2 receptors in striatal projection neurons, regardless of the CB 1 receptor expression gradient (po0.001 Student's t-test). We also quantified coexpression in experiments where the CB 1 receptor probe was labeled with digoxigenin and the neuropeptides were labeled with 35 S, yielding nearly identical results (data not shown).
Expression of CB 1 Receptors in Molecularly Identified Striatal Interneurons
To determine whether CB 1 receptors in the striatum are expressed in the interneurons and if so, in which subpopulation, we conducted dual-label hybridization experiments with 35 S-labeled riboprobe for CB 1 receptor in combination with digoxigenin-labeled riboprobes for four striatal interneuronal markers: Som, PVB, ChAT, and GAD67. For quantitative analysis, a set of slides representing material from three or four different brains was prepared and hybridized simultaneously using a single batch of 35 S-cRNA probe for CB 1 receptor together with each of the four digoxigenin-labeled riboprobes. These slides were processed in parallel, as described above. Microscopic analysis revealed that CB 1 receptors are expressed in PVB-and GAD67-containing interneurons, with a signal intensity similar to that seen in the projection neurons ( Figure 5 ). The majority of these two types of interneurons expressed CB 1 receptors, independent of their location within the striatum. We observed a lateromedial gradient for CB 1 receptors and for PVB, with more doublelabeled cells present in the lateral striatum. Neither cholinergic nor somatostatinergic interneurons expressed CB 1 receptors: we did not find any ChAT-or SOM-positive neurons that were also positive for CB 1 receptor in any of the hemispheres examined.
The Anandamide Uptake Blocker, AM404, Reduces D 1 and D 2 Receptor-Mediated Grooming, and Oral Responses
To investigate the functional significance of the anatomical colocalization of D 1 and D 2 dopamine receptors with CB 1 receptors in the striatum, we studied the effect of increasing cannabinoid tone on behaviors mediated by D 1 and D 2 receptors. Previous studies have shown that the D 1 receptor agonist SKF38393 increases grooming, while treatment with quinpirole, a D 2 preferred agonist, markedly reduced this response (Molloy and Waddington, 1987) . We used the anandamide uptake blocker AM404 to elevate endogenous extracellular cannabinoid levels. AM404 has been shown to increase levels of both major endogenous cannabinoids: anandamide (Beltramo et al, 1997, 2000) , and 2-AG (Bisogno et al, 2001 ). AM404 elicited a significant reduction in SKF38393-induced grooming but had no effect on quinpirole-induced reduction of grooming behavior (Figure 6a ). These results indicate that increased anandamide levels impact grooming behavior after D 1 but not after D 2 receptor stimulation, suggesting that CB 1 receptors may have an inhibitory role in this complex motor sequence mediated by dopamine D 1 receptors. The inhibitory effect of AM404 was reversed by the cannabinoid CB 1 receptor antagonist SR141716A, which increased grooming behavior. SR141716A also reverses the quinpirole effects on grooming by antagonizing the CB 1 receptor-mediated inhibition of dopamine D 1 receptors-mediated actions (Figure 6a ). In addition, the cannabinoid CB 1 receptor agonist HU-210 suppresses grooming induced by SKF38393 (Table 1) , again confirming the inhibitory role of this cannabinoid receptor on dopamine D 1 receptor-induced grooming. We also examined oral movements, which are significantly increased following quinpirole treatment in rats (Figure 6b ; po0.05). AM404 and SKF81297 given alone or together had no effect on the basal level of oral movements, indicating that this behavior is regulated by the activation of dopamine D 2 receptors (Figure 6b ). Interestingly, a 15-min pretreatment with AM404 significantly reduced the induction of oral movements by quinpirole. The inhibitory effect of AM404 was reversed by the cannabinoid receptor antagonist SR141716A (Figure 6b ) and mimicked by the cannabinoid CB 1 receptor agonist HU-210 (Table 1) . Taken together, these results indicate that CB 1 receptors have an inhibitory effect on D 2 R-mediated oral behavior in rats.
Opposing Effects of Cannabinoids and Dopaminergic Agents on Rotation
ANOVA indicated significant dose effects after intrastriatal infusion of SKF38393 (F(2, 29) ¼ 45, po0.01), SR141716A (F(2, 29) ¼ 88, po0.01), and AM404 (F(2, 29) ¼ 65, po0.01). Thus, as it has been shown previously, intrastriatal infusion of either SKF38393, a D 1 receptor agonist, or SR141716A, a specific CB 1 receptor antagonist, significantly increased contralateral turns (po0.01, Figure 7a ). By contrast, intrastriatal infusion of AM404 dose-dependently increased ipsilateral turns (po0.05 vs vehicle-treated animals), while neither dose of quinpirole (1 or 2.5 mg/ml) or bromocriptine (5 and 10 mg/ml) had any effect on turning behavior. These data indicate that motor function in the injected striatum was increased after D 1 receptor agonism or CB 1 receptor antagonism, while AM404, an indirect CB 1 agonist, causes a motor depression indicated by the direction (ipsilateral) and number of turns. Activation of D 2 receptors with either quinpirole or bromocriptine does not affect rotation (Figure 7a ).
To investigate whether the cannabinoid system can also modify turning behavior induced by dopamine agonists, we increased or decreased CB 1 receptor activity and examined the effect on rotation induced by intrastriatal injection of the dopaminergic agent SKF38393 (we did not use quinpirole or bromocriptine since they had no independent effects on rotation). Two-way ANOVA revealed a significant interaction effect of SKF38393 in combination with cannabinoid ligands (F(6, 72) ¼ 34.3, po0.01). Pretreatment with the CB 1 receptor antagonist SR141716A (1.5 mg/ml) 5 min before intrastriatal injection of SKF38393 results in potentiation of contralateral turns induced by SKF38393 alone. This potentiation occurred at 1 mg/ml SKF38393 (po0.01 vs either SR141716A or SKF38393 alone; Figure 7b ). By contrast, pretreatment with AM404 (5 mg/ ml) significantly reduced contralateral turning induced by 1 mg/ml SKF38393 (po0.05 vs either AM404 or SKF38393 alone; Figure 7b ). This effect was blocked when SR141716A (1.5 mg/ml) was injected before AM404 (Figure 7b ). Thus D 1 receptor function is enhanced by blockade of CB 1 receptors and reduced by increasing concentration of the endogenous CB 1 receptor agonist anandamide through AM404 infusion. The effect of AM404 seems to be mediated by CB 1 receptors since it is blocked by SR141716A. For all experiments involving intrastriatal injection, we confirmed the injection site histologically and only those animals where the injection site was found to be correct were analyzed. Figure 7c illustrates the central cannula tip location in the left striatum, and Figure 7d shows a representative coronal section stained with the Nissl technique. Inspection of brain tissues revealed evidence of a small lesion and gliosis at the site of injection, although surrounding tissue was generally intact. Blocking CB 1 receptors with SR141716A enhanced the duration of grooming in wild-type mice (po0.01), but had no effect on grooming in dopamine D 1 R À/À (Figure 8a ). This indicates that the effect of SR141716A on grooming behavior is mediated by D 1 receptors, probably due to release of inhibitory endocannabinoid tone that modulates endogenous dopamine D 1 receptormediated behaviors. The D 1 agonist SKF81297 enhanced grooming in wild-type mice (po0.01), but had no effect on grooming in dopamine D 1 R À/À , confirming the selectivity of SKF81927 for D 1 receptor. AM404 had no significant effect on grooming in wild type or D 1 R À/À mice. Confirming the data shown in Figure 6 , AM404 reduced the effect of SKF81927 in wild-type animals. There was no effect of either of these drugs alone or together in D 1 R À/À mice (Figure 8 ). Paxinos and Watson (2005) . Distance to Bregma is indicated. (d) Representative photo of an injection site in a coronal brain section stained with Nissl technique (the border of the nucleus is drawn with a dashed line). We discarded all data from animals in which histology revealed that the cannula tip was located outside the striatum. Str, striatum.
Studies in Wild-
DISCUSSION
This study provides evidence that the endogenous cannabinoid system is a relevant negative modulator of dopamine D 1 and D 2 receptor-mediated behaviors through its actions on striatal neurons expressing dopamine receptors. The double-hybridization data presented in this study demonstrate that both types of striatal projection neurons as well as some interneurons in the striatum express and synthesize CB 1 receptors. The distribution of CB 1 receptors in the striatum showed a lateromedial gradient, confirming previous results (Herkenham et al, 1990 (Herkenham et al, , 1991 Tsou et al, 1998; Hermann et al, 2002; Julián et al, 2003) . In addition, the present study reveals that the extent of CB 1 receptor mRNA expression is different in direct and indirect striatal output pathways. Our quantitative studies indicate that approximately 40% of striatal cells expressing CB 1 receptors are dopamine D 2 receptor-containing indirect projection neurons, and the remaining 60% are D 1 receptor-containing direct projection neurons. The present study also showed that CB 1 receptors are expressed by PVB and GAD67 interneurons, which are found primarily in close proximity to the cortex. Chemical stimulation of the cortex activates these interneurons, inducing expression of transcription factor genes (Berretta et al, 1999) . Curiously enough, PVB and GAD67 interneurons express dopamine D 2 (Rivera et al, 2002a) , but not D 1 receptors, suggesting that interaction between endocannabinoids and the dopamine system in the cortex could be via dopamine D 2 receptors on striatal interneurons. PVB neurons also express D 5 receptors (Rivera et al, 2002b) , which are activated by D 1 receptor ligands.
The colocalization of CB 1 receptors with both dopamine D 1 and D 2 receptors indicates that these receptors may interact, potentially modifying their respective functions with important behavioral and pharmacological consequences. Supporting this notion, there are several studies suggesting the interaction between CB 1 receptors and dopamine D 2 receptors at the cellular level (Glass and Felder, 1997; Kearn et al, 2005) . Previous reports have demonstrated a general inhibitory effect of exogenous cannabinoids on dopamine-mediated behaviors (Rodriguez de Fonseca et al, 1998) . Activation of CB 1 receptor in the striatum is associated with a general inhibition of motor behaviors, resulting in long-term changes in striatal synaptic plasticity (Ronesi et al, 2004) . However, there has been little information on the specific functional neuroanatomy of these interactions. We assessed some of the behavioral results of these putative interactions. Striatal dopamine D 1 and D 2 receptors are critical for striatal control of motor function. Neurons expressing D 1 receptors form the direct pathway, which projects to internal globus pallidus and substantia nigra, while neurons expressing D 2 receptors make up the indirect pathway, projecting to external globus pallidus (McKenzie et al, 1984; Paul et al, 1992; O'Connor, 1998; Nicola et al, 2000; Svenningsson et al, 2000; Onn et al, 2000) . Dopamine is a relevant modulator of striatal excitatory inputs from the cortex, generally facilitating motor behavior (initiation, sequencing, and ending of movement, Hauber, 1998) . In addition, there are several behaviors that can be elicited by specific stimulation of either dopamine D 1 or D 2 receptors. These behaviors can be used as a read-out for functional evaluation of the different striatofugal pathways (Aldridge and Berridge, 1998) and their modulation by the endocannabinoid system. In rodents, dopamine D 1 receptor stimulation elicits complex motor sequencing such as grooming behavior, while stimulation of dopamine D 2 receptors enhances horizontal locomotion and produces stereotypical oral movements. In the present study, we selected grooming and oral stereotypies as read-out behaviors for dopamine D 1 and D 2 receptor stimulation, respectively (Giuffrida et al, 1999; Molloy and Waddington, 1984; Starr and Starr, 1986a, b) .
It is generally accepted that the endocannabinoid system in the basal ganglia plays a key role in adjusting synaptic transmission within striatal synapses, acting as a retrograde messenger on glutamatergic or gabaergic inputs, or directly modulating postsynaptic signal transduction at dopamine receptors (Glass and Felder, 1997; Mato et al, 2004; Rodriguez de Fonseca et al, 1998) . Supporting this hypothesis, pharmacological stimulation of both dopamine D 1 and D 2 receptors seems to enhance anandamide production in the basal ganglia, possibly triggering negative feedback regulation of dopamine effects (Ferrer et al, 2003; Giuffrida et al, 1999) . This inhibitory role on synaptic transmission is reflected in cannabinoid CB 1 receptor- mediated inhibition of dopamine D 1 and D 2 receptormediated behaviors (Rodriguez de Fonseca et al, 1994) , and the present study confirms this negative interaction on several behavioral responses. To explore the effects of endogenous cannabinoids (anandamide and 2-arachidonoylglycerol), we used AM404 to block reuptake, effectively increasing their concentrations (Beltramo et al, 1997 (Beltramo et al, , 2000 Bisogno et al, 2001) . We found that indirect activation of CB 1 receptors by AM404 inhibits grooming, a dopamine D 1 receptor-mediated response, suggesting negative regulation of D 1 receptor responses by endogenous cannabinoids via CB 1 . These data showed that dopamine D 2 receptors also appear to impact grooming behavior, because the D 2 receptor agonist quinpirole reduced grooming behavior, pointing to opposite modulation of this behavior by D 1 and D 2 receptors, as seen previously (Starr and Starr, 1986a, b) . Modulation of endocannabinoid levels by AM404 did not apparently influence the inhibitory activity of quinpirole in grooming, possibly due to an already floor effect reached by quinpirole. However, administration of SR141716A reverses the suppression of grooming induced by the combined administration of quinpirole and AM404, clearly indicating the interaction of CB 1 and D 2 receptors, mutually opposing to D 1 receptor-mediated facilitation of self-grooming.
Stereotypical oral movements are a characteristic response to D 2 stimulation in rodents, and they seem to be modulated at the striatal level (McPherson and Marshall, 1996; Davidkova et al, 1998) . Confirming previous results, we found that D 1 stimulation did not affect oral responses, while D 2 agonist clearly induced oral stereotypies in rats. Cannabinoid CB 1 receptor stimulation blocked D 2 -induced oral stereotypies. This finding points to a negative interaction between D 2 and CB 1 receptors in the striatum with respect to oral stereotypies, as has been described for horizontal locomotion (Giuffrida et al, 1999) . This has important therapeutic implications since oral stereotypies are side-effects of prolonged dopaminergic stimulation in humans including neuroleptic treatment for psychosis and levodopa therapy for Parkinson's disease. Our results suggest that CB 1 agonism has therapeutic potential for reducing the incidence of these abnormal oral responses. In this context, there is evidence that drugs that enhance the activity of the endocannabinoid system may have the capacity to suppress or prevent unwanted dyskinesias in Parkinsonian patients (Ferrer et al, 2003) , without affecting the beneficial D 1 and D 2 effects of L-DOPA.
A potential contribution of other targets of anandamide and AM404 (eg the vanilloid VR1 receptor) to the inhibition of dopamine-mediated behaviors cannot be excluded (De lago et al, 2004; Tzavara et al 2006) . However, we obtained pharmacological confirmation of the involvement of the CB 1 receptor in AM404 action on dopamine-mediated behaviors. Administration of the CB 1 agonist HU-210 suppressed both D 1 receptor-mediated grooming and D 2 receptor-mediated oral stereotypies. Furthermore, the inhibitory actions of AM404 and HU-210 were reversed by administration of the CB 1 receptor antagonist SR141716A. Thus, although activation of vanilloid receptors may exert antidopaminergic actions, our results confirm that the effects we see are mediated by cannabinoid CB 1 receptors.
At the local striatal level, our results revealed that intrastriatal D 1 (but not D 2 ) receptor activation enhanced motor function, leading to contralateral rotations. From a functional point of view, stimulation of D 1 receptors would resemble physiological effects of dopamine, leading to a net excitation of neurons of the motor cortex (Löschmann et al, 1997; Onn et al, 2000) . In this context, D 1 receptor agonism in the striatum has been reported to stimulate motor function: intrastriatal administration of SKF38393 increased movements in rats (You et al 1994) . We found that manipulating CB 1 function with cannabinoid ligands modified D 1 -induced motor responses: CB 1 antagonism enhanced D 1 -induced motor responses and CB 1 activation blocked them, again indicating a negative interaction between D 1 and CB 1 receptors. Although AM404 can also influence TRPV1 vanilloid receptors (Zygmunt et al, 2000) , AM404-mediated effects on SKF-induced rotation were blocked by SR141716A, indicating that the AM404 effect is mediated by CB 1 receptors. As reported previously, D 2 stimulation with quinpirole or bromocriptine had no effect on rotation (Sañudo-Peña et al, 1998a) . Many studies have shown that D 2 receptor activation only modifies turning responses in rats with unilateral striatal denervation, probably due to compensatory overexpression of D 2 receptors (El Banoua et al, 2004) . In summary, intrastriatal infusion of cannabinoid CB 1 receptor antagonist stimulates motor activation, while CB 1 receptor agonist inhibits it. Since activation of CB 1 receptor counteracts the stimulatory effects of D 1 receptor agonists, as shown previously (Sañudo-Peña et al, 1998a) , the effects of CB 1 receptor ligands are likely to be due to their modulation of the effects of endogenous dopamine at D 1 receptors.
We further analyzed this relationship using dopamine D 1 receptor knockout (D 1 R À/À ) mice. In mice, as in rats, grooming is a characteristic behavior associated with selective stimulation of D 1 receptors (Starr and Starr, 1986a, b) . Our findings confirmed that this response is activated after D 1 receptor stimulation, and disappears in mice lacking dopamine D 1 receptors. Grooming is also stimulated after CB 1 antagonism, and this effect is mediated by D 1 receptors since it does not take place in dopamine D 1 R À/À mice. In addition, grooming is further enhanced after D 1 stimulation and CB 1 receptor blockade, indicating that D 1 and CB 1 receptors have opposing effects on grooming. Because we did not observe enhanced grooming in D 1 R À/À mice after cannabinoid CB 1 receptor blockade we believe that the effects of CB 1 receptor blockade in wild-type mice are due to baseline cannabinoid tone that inhibits dopamine D 1 -mediated behavior. We found that WT mice treated with AM404 have more grooming than control mice treated with vehicle, although this response is fourfold lower than that observed after D 1 receptor stimulation. Moreover, pretreatment with AM404 completely abolished the potent response induced by the dopamine agonist. None of these effects induced by SKF81297 were observed in D 1 R À/À mice suggesting critical dependence on D 1 receptors. The small increase observed after AM404 in grooming behavior in both WT and D 1 R À/À mice may be related to alternative targets implicated in grooming as indicated elsewhere (ie a potential stress response induced by AM404 injection, since stress induces grooming in mice (Kalueff and Tuohimaa, 2005) .
Our study demonstrates that CB 1 mRNA is colocalized both with dopamine D 1 receptors in direct striatal projection neurons and with D 2 receptors in indirect striatal projection neurons. This allows endogenous cannabinoids acting at CB 1 receptors to modulate not only the afferent glutamatergic inputs into the striatum but also the efferent inhibitory outputs of the medium spiny neurons to their projection fields in the midbrain, as shown in the diagram of the basal ganglia motor circuit (Figure 9 ). These data support the hypothesis that endogenous cannabinoids act through CB 1 receptors in the striatum to inhibit dopaminemediated motor behaviors, including dopamine D 1 receptor-mediated grooming behavior, D 1 receptor-induced turning response, and D 2 receptor-induced oral stereotypies. It has been reported that CB 1 agonists facilitate dopaminergic activity in the nucleus accumbens (French et al, 1997) . It may seem that this contradicts our findings, but in fact, due to the complexity of basal ganglia circuitry as shown in Figure 9 , it is consistent with our results. The interaction between CB 1 and D 1 receptors in dorsal striatum decreases the inhibitory input of striatal projection neurons onto dopaminergic neurons in the VTA and SN that project to the nucleus accumbens and to the striatum, enhancing their activity.
Functional interactions between dopamine D 1 and D 2 receptors , and the CB 1 receptor could occur due to direct receptor-receptor interaction (Kearn et al, 2005) or indirectly, via intracellular signaling pathways (Glass and Felder, 1997) or via effects on cells in different regions of the motor circuit. Since dopamine D 1 and D 2 receptors, and the CB 1 receptor all regulate adenylyl cyclase (AC), this common pathway is one likely site for interaction. Activation of CB 1 and D 1 receptors together results in a net decrease in adenylyl cyclase, causing a decrease in the inhibitory activity of direct striatal projection neurons, which enhances the activity of nigral neurons and results in decreased motor response (Figure 9 ). Conversely, activation of CB 1 and D 2 receptors together stimulates adenylyl cyclase (Glass and Felder, 1997) , potentiating the indirect striatal pathway neurons that in turn activate neurons of the subthalamic nuclei, also resulting in decreased movement. Although this scenario is in good agreement with our results, additional work is needed to determine whether the effect of CB 1 R activation on D 1 and D 2 -mediated behaviors is in fact mediated via the adenylyl cyclase signaling pathway. Whatever the mechanism, these data indicate that endogenous cannabinoids acting at striatal CB 1 receptors play a significant role in the regulation of basal ganglia motor circuits. Diagram of the basal ganglia motor circuit. This simplified diagram shows the main connections between regions in the basal ganglia motor circuit. Cannabinoid CB 1 receptors are present on both, striatonigral gabaergic projection neurons, which also express D 1 receptors, and striopallidal gabaergic projection neurons, which express D 2 receptors. The location of CB1 receptors allows the cannabinoids to modulate both afferent glutamatergic inputs into the striatum and also the efferent inhibitory outputs from the medium-spiny projection neurons. Activation of CB 1 and D 1 receptors results in a net decrease in adenylyl cyclase activity, causing a decrease in the inhibitory activity of direct striatal projection neurons, which enhances the activity of nigral neurons and results in decreased motor response. Conversely, simultaneous activation of CB 1 and D 2 receptors stimulates adenylyl cyclase, potentiating the indirect striatal pathway neurons that in turn activate neurons of the subthalamic nuclei, also resulting in decreased movement. Globus pallidus (GP); subthalamic nucleus (STN); substantia nigra (SN).
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